Human C-peptide in normal and diabetic subjects
Home > peptide news

Concentrations of C-, IRI (immunoreactive ) and were determined during oral tolerance test (1.75 g /kg ideal body weight) in 14 normal persons (N), 9 maturity-onset diabetics (DI) and 10 -requiring diabetics () never treated with and in 3 formerly treated diabetics. The mean fasting levels of C-and: N: 0.37 +/- 0.02 nM and 0.048 +/- 0.009 nM, DI: 0.86 +/- 0.17 nM and 0.11 +/- 0.029 nM, DH: 0.37 +/- 0.04 nM and 0.063 +/- 0.009 nM. One hour after oral ingestion, the respective values increased to: N: 2.53 +/- 0.20 nM and 0.52 +/- 0.077 nM, DI: 2.49 +/- 0.31 nM and 0.49 +/- 0.11 nM, DH: 0.49 +/- 0.05 nM and 0.11 +/- 0.014 nM. Although secreted from the pancreas in equimolar concentrations, the molar ratio of C-to in peripheral blood was about 7 in the fasting state, falling to about 5 in the stimulated condition. Human C-peptide in normal and diabetic subjects.Maturity-onset diabetics had higher fasting levels of C-than normal subjects, in agreement with the IRI levels. Three patients previously treated with and having showed C-responses significantly below the normal range. In one of these patients, the test was repeated 9 months later when the had disappeared, and the C-response observed at that time was much higher. It is suggested that cause an impaired IRI - and consequently C-response - by constantly removing from the granules in the B-. In normal the peripheral C-responses to the oral load showed less relative variation than do the responses. Therefore, a radioimmunoassay for C-in addition to the assay for will provide supplementary information on .


prev£ºDeterminants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients

next£ºUse of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid.